Wockhardt says MHRA passes Chikalthana plant; Biocon buys potent API facility;

> India's Wockhardt reported to the Bombay Stock Exchange that the U.K.'s MHRA inspected and passed its plant in Chikalthana, a facility that the FDA has banned and to which it has issued a warning letter. Report

> India's Biocon last week reported that it had bought from Vishakhapatnam-based Acacia Lifesciences a manufacturing facility that makes intermediates of potent active pharma ingredients (APIs). Report

> Merck Millipore, the CMO operation of Merck KGaA, has formed a collaboration with celares GmbH that will provide pegylation services to customers developing protein-based therapeutics and biosimilars. Release

> Egyptian regulators, who estimate that 2% of the products in pharmacies are counterfeits or expired, will collect them from pharmacies and make manufacturers accept returns of expired product. Story

Suggested Articles

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.